Summer school programme:
5th of September
10.00 – 10.10 Welcome - Magdalena Kowalewska and Michał Mikula
10.10 – 11.40 Ryszard Konopiński, Damian Garbicz, Daniel Bajerski, Monika Świątek – Nanobody technology as a black horse in contemporary medical science.
11.40 -12.00 From Sample Collection to Actionable Results – automate your workflow with Eppendorf
12.00 – 13.00 lunch
13.00 – 13.30 Tomasz Sarnowski - Nanobody in use – perspectives
13.30 – 14.30 Radosław Zagożdżon - CAR-T technology
14.30-15.00 Leszek Kotula - The power of genetic models to study human cancer
15.00 – 15.20 coffee
15.20- 16.00 Aneta Montano - Is salutogenic oncoimmuno coaching a superior form of psychological support of oncological patients?
6th of September
10.00 – 11.30 Eileen Kennedy, University of Georgia, USA - Chemical biology of kinases
11.30 - 11.45 coffee
11.45- 13.15 Richard Bayliss, University of Leeds, UK- Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors
13.15- 14.15 lunch
14.15 - 15.45 Josephina Sampson, University of Leeds, UK - Imaging cells and biomolecular condensates
15.45 - 16.45 Alfonso Urbanucci Tampere University, Finland - A take of 15 years of prostate cancer research: from PhD to PI.
16.45- 17.00 Piotr Trzonkowski Medical University of Gdańsk, PolTREG S.A - T regulatory cells - from bench to bedside.
During the days of the conference, speakers and panellists will be available to participants of the Summer School
Conference programme:
7th of September
9.10-9.30 Welcome - Michal Mikula
"Holistic view on patient's care" Aneta Montano
Session 1. Molecular oncology of kinases
Chair: Eileen Kennedy
9.30-10.00 Understanding and targeting oncogenic biomolecular compartments of ALK kinase (Josephina Sampson, University of Leeds, UK)
10.00-10.30 Targeting the G2 phase decatenation checkpoint: an emergent, tumour-specific vulnerability (Tanya Soliman, Barts Cancer Institute, London, UK)
10.30-10.45 Mixed-Lineage Kinase 4 in breast cancer progression and chemoresistance (Anna Marusiak - IMOL)
10.45-11.00 Coffee break and refreshments
11.00-11.15 Oncogenic PIM kinases support malignant cell survival and regulate their interactions with tumor microenvironment in cHL and PMBL (Maciej Szydłowski, PhD - IHiT)
11.15-11.30 AXL kinase signaling in cancer cell biology (Daria Zdżalik-Bielecka, IIMCB)
11.30-12.00 Structure, function and pharmacology of oncogenic RET fusions products
(Ivan Plaza-Menacho, CNIO Madrid, Spain)
12.00-13.00 LUNCH
Session 2. Kinase inhibitors in the clinic
Chair: Tanya Soliman
13.00-13.30 Success and limitations of kinase inhibitors in Oncology (Petros Christopoulos, Thoraxklinik, University of Heidelberg, Germany)
13.30-13.50 RNA deregulation affects the interplay between keratinocytes and immune cells modulating susceptibility to skin cancer (Jolant Jura, Jgiellonian University, Cracow, Poland)
13.50-14.20 TKI in haematological malignancies (Martin Dyer, University of Leicester, UK)
14.20- 14.40 Coffee break and refreshments
Session 3. Kinase inhibitor discovery
Chair: Martin Dyer
14.40-15.10 Allosteric targeting of oncologic kinases using constrained peptides
(Eileen Kennedy, University of Georgia, USA)
15.10-15.20 ALPK1 mutants causing spiradenocarcinoma are activated abnormally by allosteric activators. (T Snelling)
15.20-15.30 Using single-molecule spectroscopy to measure conformational changes in c-Met kinase with clinically arising resistance mutations (TSA Wilcock)
15.30-15.50 Perspective on kinase drug discovery (Richard Bayliss, University of Leeds, UK)
15.50-16.00 Identification of new molecular alterations in clear cell renal cell carcinoma and designing a platform based on VHHs from Alpaca to develop future anticancer therapy (Paweł Ćwiek)
Allosteric inhibition of Anaplastic Lymphoma Kinase (ALK) by single-domain antibodies (Nan Zhang)
16.00-16.30 Panel discussion all invited speakers
16.30- 17.30 ** Poster session ** together with coffee break and refreshments
Session 4. CAR-T technology
Chair: Radosław Zagożdżon and Grzegorz Basak
17.30 – 17. 50 Driving of CARs to the new directions- locally produced CART cells for the treatment of plasma cell dyscrasia ( Polina Stepensky: Hadassah Medical Center, Israel)
17.50 – 18.20 Recent development in CAR-T therapy in NHL (Grzegorz Basak: Warsaw Medical University, Poland)
18.20- 18.40 Challenges and solutions for CAR-based strategies against solid tumors (Radosław Zagożdżon:Warsaw Medical University, Poland )
18.40 – Dinner
8th of September
Session 1. Gene expression control in cancer
Chairs: Tomasz Sarnowski and Agata Starosta
9.00 – 9.20 Novel aspects of Cathepsin S hyperactivity in cancer (Johannes Hildebrand, LMU, Germany)
9.20-9.40 Inhibition of RNA polymerase III augments the anti-cancer properties of TNF-alpha (Damian Graczyk, IBB PAS, Warsaw, Poland)
9.40-10.00 Cellular metabolome of cancer line HT 1080 in response to external conditions (Piotr Młynarz, Wrocław University of Science and Technology, Wrocław, Poland)
10.00-10.20 The crosstalk of NF-κB and p53 transcription factors in irradiated cancer cells (Piotr Widłak, MSCNRIO, Gliwice, GUMED. Gdańsk, Poland)
10.20-10.20 coffee break
Session 2. Prostate Cancer translational research
Chairs: Alfonso Urbanucci and Paweł Wiechno
10.30-10.55 “Role of ABI1 in prostate cancer” (Leszek Kotula, Upstate Medical University, USA)
10.55-11.20 “An overview of clinical trials in the Nordics in urological cancers” ( Teemu Murtola, Tampere University, Finland).
11.20- 11.45 Strategies to improve radiotherapy for prostate cancer patients: the radio-oncology perspectiv (Wolfgang Lilleby, Oslo University Hospital, Norway)
11.45-12.00 Prostate Cancer - Is Treating Earlier Always Better? (including a summary of the session) (Paweł Wiechno: MSCNRIO, Poland)
12.00 -13.00 – lunch
Session 3. Immunooncology
Chairs: Jadwiga Jabłońska and Natalia Marek-Trzonkowska
13.00-13.20 Potential and limitations of neutrophils as valid cancer biomarkers (Jadwiga Jabłońska, University Hospital Essen, Germany)
13.20-13.35 Choosing the Optimal Therapy for Renal Cell Carcinoma. How to combine clinical and basic science approach? (Jakub Kucharz, MSCNRIO, Warsaw, Poland)
13.35-14.50 panel discussion: Holistic approach to cancer immunotherapy.
chaired by Jadwiga Jabłońska and Natalia Marek-Trzonkowska;
panelists: Piotr Trzonkowski, Maciej Chałubiński, Richard Bayliss, Jakub Kucharz, Petros Christopoulos, Radoslaw Zagozdżon, Martin Dyer
14.50- 15.00 Coffee break
Session 4. Gliwice session: New perspectives in anticancer therapy
Chairs: Tomasz Cichoń and Ryszard Smolarczyk
15.00-15.20 Advances in molecular diagnostics and therapy of pancreatic cancer - state of the art and perspectives (Ujjwal Mukund Mahajan: LMU University Hospital, Munich, Germany
15.20-15.40 Endoscopic Ultrasound-Guided Local Therapies for Pancreatic Neoplasms - New Hope or Dead End? (Michał Żorniak: MSCNRIO, Gliwice, Poland)
15.40-16.00 Repositioning of drugs in in vitro studies as a potential direction of searching for new form of pharmacotherapy (Artur Beberok: Medical University of Silesia)
16.00 - 16.20 Combination of auranofin and syrosingopine as a new anticancer therapy (Tomasz Cichoń: MSCNRIO, Gliwice, Poland; Jerzy Gubernator: University of Wrocław; Wiesław Szeja; Ryszard Smolarczyk: MSCNRIO, Gliwice)
16.20 closing remarks